Decnupaz Approved for Blastic Plasmacytoid Dendritic Cell Neoplasms

Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHA new treatment option, pivekimab sunirine-pvzy (Decnupaz, AbbVie), has been approved for blastic plasmacytoid dendritic cell neoplasm, a rare type of hematologic malignancy.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:trans